Published: Sat, January 13, 2018
Business | By Tara Barton

GlaxoSmithKline plc (GSK) Given Average Rating of "Hold" by Brokerages


Bank of America upgraded GlaxoSmithKline plc (NYSE:GSK) on Tuesday, September 8 to "Neutral" rating. Hedge funds and other institutional investors own 9.82% of the company's stock. Hotchkis & Wiley Capital Management LLC grew its position in GlaxoSmithKline by 7.3% in the third quarter.

Accern also gave news headlines about the pharmaceutical company an impact score of 46.6510607046145 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Renaissance Technologies LLC increased its stake in GlaxoSmithKline by 112.1% in the 2nd quarter.

The company's stock is now moving with a -ve distance from the 200 day SMA of approximately -9.08%, and has a solid year to date (YTD) performance of 2.62% which means that the stock is constantly adding to its value from the previous fiscal year end price. The company's stock had a trading volume of 1,813,600 shares. Northern Trust Corp now owns 3,078,478 shares of the pharmaceutical company's stock worth $132,743,000 after purchasing an additional 85,830 shares during the last quarter. Point72 Asset Management L.P. increased its stake in GlaxoSmithKline by 504.4% in the 3rd quarter. The Oak Ridge Investments Llc holds 447,963 shares with $29.54M value, up from 405,772 last quarter. Finally, Seatown Holdings Pte.

In other GlaxoSmithKline news, insider Simon Dingemans purchased 1,076 shares of the firm's stock in a transaction that occurred on Thursday, October 12th. The company now has a consensus rating of "Buy" and an average target price of $47.25. Insiders own 10.00% of the company's stock.

Adobe Systems Incorporated (ADBE) Director Purchases 1125 Shares of Stock
Gabelli Funds Limited Com holds 0.04% or 200,000 shares in its portfolio. 290,881 shares of the company's stock were exchanged. The stock of Adobe Systems Incorporated (NASDAQ:ADBE) has "Buy" rating given on Thursday, October 19 by Bank of America.

Several equities research analysts have commented on the stock. Bank of America upgraded the shares of GSK in report on Wednesday, December 9 to "Buy" rating. Investec lowered shares of GlaxoSmithKline to a "hold" rating and lowered their price target for the company from GBX 1,800 ($24.07) to GBX 1,390 ($18.59) in a report on Monday, November 6th. The firm has "Hold" rating given on Thursday, October 26 by Bank of America. Bryan Garnier & Cie upgraded GlaxoSmithKline plc (NYSE:GSK) on Wednesday, January 27 to "Buy" rating. (NASDAQ:BIIB) rating on Wednesday, November 8. Tenaris S.A. (NYSE:TS) has risen 25.06% since January 7, 2017 and is uptrending. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58. The firm has a market cap of $89,240.00, a P/E ratio of 28.64, a PEG ratio of 2.15 and a beta of 0.97. Stockholders of record on Thursday, November 9th will be given a GBX 19 ($0.26) dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a yield of 1.41%. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.49. GlaxoSmithKline's payout ratio is 154.26%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of US and global copyright & trademark legislation. About 10.16M shares traded.

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Like this: